Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Doxorubicin–Trabectedin with Trabectedin Maintenance in Leiomyosarcoma
Patricia Pautier, Antoîne Italiano, Sophie Piperno‐Neumann, et al.
New England Journal of Medicine (2024) Vol. 391, Iss. 9, pp. 789-799
Closed Access | Times Cited: 29

Showing 1-25 of 29 citing articles:

Gynecologic oncology in 2024: breakthrough trials and evolving treatment strategies for cervical, uterine corpus, and ovarian cancers
Sung Jong Lee, Ji Geun Yoo, Jin Hwi Kim, et al.
Journal of Gynecologic Oncology (2025) Vol. 36, Iss. 1
Open Access | Times Cited: 1
Precisely Tailoring Molecular Structure of Doxorubicin Prodrugs to Enable Stable Nanoassembly, Rapid Activation, and Potent Antitumor Effect
Chengcheng Feng, Yuting Wang, Jinghua Xu, et al.
Pharmaceutics (2024) Vol. 16, Iss. 12, pp. 1582-1582
Open Access | Times Cited: 5
Long-term disease control in dedifferentiated liposarcoma: a case report on trabectedin priming followed by PD-1 inhibition
Johannes M. Waldschmidt, Lukas Haug, Christine Riedhammer, et al.
Frontiers in Oncology (2025) Vol. 14
Open Access
Clinical practice guidelines for uterine corpus cancer: an update to the Korean Society of Gynecologic Oncology guidelines
Woo Yeon Hwang, Ju-Hyun Kim, Joseph J. Noh, et al.
Journal of Gynecologic Oncology (2025) Vol. 36, Iss. 1
Open Access
Emerging treatments for sarcoma: from 2024 onward
Diego Gómez-Puerto, Carlo María Cicala, Claudia Valverde, et al.
Expert Opinion on Emerging Drugs (2025)
Closed Access
Doxorubicin and trabectedin in leiomyosarcoma: pioneering a new era of smart combinations in soft tissue sarcomas
Tarek Assi, Axel Le Cesne
Future Oncology (2025), pp. 1-4
Closed Access
SaLudo: a randomized phase IIb/III study of lurbinectedin plus doxorubicin as first-line treatment in leiomyosarcoma
Gregory M. Coté, Sant P. Chawla, George D. Demetri, et al.
Future Oncology (2025), pp. 1-9
Open Access
Development of Antibody–Drug Conjugates for Malignancies of the Uterine Corpus: A Review
T. Yamanaka, Tadaaki Nishikawa, Hiroshi Yoshida
Cells (2025) Vol. 14, Iss. 5, pp. 333-333
Open Access
Doxorubicin Plus Dacarbazine Versus Doxorubicin Plus Ifosfamide in Combination With Regional Hyperthermia in Patients With Advanced Leiomyosarcoma: A Propensity Score‐Matched Analysis
Luc M. Berclaz, Vindi Jurinović, Anton Burkhard‐Meier, et al.
Cancer Medicine (2025) Vol. 14, Iss. 4
Open Access
Characterizing Cardiotoxicity of FDA-Approved Soft Tissue Sarcoma Targeted Therapies and Immune Checkpoint Inhibitors: A Systematic Review
Mustafa Houmsse, Andrew Muskara, Damaris Pasca, et al.
Cancers (2025) Vol. 17, Iss. 5, pp. 827-827
Open Access
Systemic Treatment in Soft Tissue Sarcomas: Are We Making a Difference?
Amrit Paudel, P. K. Chattopadhyay, B. Rose, et al.
Cancers (2025) Vol. 17, Iss. 5, pp. 889-889
Open Access
Gemcitabine Plus Docetaxel, Dacarbazine, Doxorubicin Combinations, or Doxorubicin Alone as First-Line Treatment for Advanced/Metastatic Leiomyosarcoma: A Retrospective Analysis at a Sarcoma Center
Ted Kim, Clara Hao, Minggui Pan, et al.
Diseases (2025) Vol. 13, Iss. 3, pp. 79-79
Open Access
Conference on Challenges in Sarcoma (CCS) 2024 Expert Opinions on Non-Evidence-based Management Aspects
Silvia Höfer, Chantal Pauli, Beata Bode‐Lesniewska, et al.
European Journal of Cancer (2025), pp. 115368-115368
Closed Access
Dexrazoxane makes doxorubicin-induced heart failure a rare event in sarcoma patients receiving high cumulative doses
Haoyi Zheng, Huichun Zhan
Cardio-Oncology (2025) Vol. 11, Iss. 1
Open Access
Retrospective Analysis of BRCA -Altered Uterine Sarcoma Treated With Poly(ADP-ribose) Polymerase Inhibitors
M.B. Rao, Madeline Merrill, Mary Troxel, et al.
JCO Precision Oncology (2025), Iss. 9
Closed Access
Regorafenib as maintenance therapy after first-line doxorubicin-based chemotherapy in advanced non-adipocytic soft tissue sarcomas patients: a double-blind randomised trial
Nicolas Penel, Antoîne Italiano, Jennifer Wallet, et al.
Annals of Oncology (2025)
Closed Access
Marine Natural Products in Inflammation‐Related Diseases: Opportunities and Challenges
Tao Zhang, Zijun Ouyang, Yueran Zhang, et al.
Medicinal Research Reviews (2025)
Closed Access
A Comprehensive Review of Chemotherapy in Localized Soft Tissue Sarcomas: Is the Cat Out of the Bag Yet?
Anand Mohan, Abhay K. Kattepur, Shraddha Patkar, et al.
Indian Journal of Surgical Oncology (2025)
Closed Access
Rare Uterine Tumors: What to Do?
Erin K. Crane, Stéphanie Gaillard, Martee L. Hensley
American Society of Clinical Oncology Educational Book (2025) Vol. 45, Iss. 3
Closed Access
Blood‐based biomarkers in soft tissue sarcoma: Implications for immune checkpoint inhibitor therapy
Brie‐Anne Mannah, John J. Park, Su Yin Lim
International Journal of Cancer (2025)
Open Access
A Late-Arriving but Welcome Advance in Sarcoma Therapy
Robert S. Benjamin
New England Journal of Medicine (2024) Vol. 391, Iss. 9, pp. 854-855
Closed Access | Times Cited: 3
Combinatorial prediction of therapeutic perturbations using causally-inspired neural networks
Guadalupe Gonzalez, Xiang Lin, Isuru Sachitha Herath, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 2
Trabectedin for L-Type Sarcoma: A Retrospective Multicenter Study
Sercan Ön, Barış Köksal, Zafer Arık, et al.
Current Oncology (2024) Vol. 31, Iss. 11, pp. 6803-6813
Open Access | Times Cited: 1
Novel Therapeutics in Soft Tissue Sarcoma
Leonidas Mavroeidis, Andrea Napolitano, Paul H. Huang, et al.
Cancers (2024) Vol. 17, Iss. 1, pp. 10-10
Open Access | Times Cited: 1
A new standard of care for leiomyosarcoma
Peter Sidaway
Nature Reviews Clinical Oncology (2024)
Closed Access
Page 1 - Next Page

Scroll to top